精准医学时代中国丙型肝炎诊疗一体化的病毒学应答指导治疗策略

周惠娟; 谢青

doi:10.3969/j.issn.1001-5256.2016.07.008

精准医学时代中国丙型肝炎诊疗一体化的病毒学应答指导治疗策略

DOI: 10.3969/j.issn.1001-5256.2016.07.008

周惠娟,
谢青

上海交通大学医学院附属瑞金医院感染科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 192
- HTML全文浏览量: 14
- PDF下载量: 126
- 被引次数: 0
出版历程
- 收稿日期: 2016-05-03
- 出版日期: 2016-07-20

Strategy for virologic response-guided therapy in integrated diagnosis and treatment of hepatitis C in the era of precision medicine in China

Department of Infectious Diseases,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine

摘要

摘要: 长效干扰素联合利巴韦林仍然是现阶段我国丙型肝炎治疗的主要手段,通过精准医疗可以让更多丙型肝炎患者实现治愈。简述了精准医学时代中国丙型肝炎诊疗情况与病毒学应答指导治疗(RGT)策略的重要性,并分析了影响获得持续病毒学应答的重要因素,其中HCV RNA检测是RGT策略的基石,治疗过程中关键时间点采用高灵敏度的HCV RNA检测可以更精准地评估应答,实现丙型肝炎个体化治疗,提高丙型肝炎治愈率。
- 肝炎,丙型 /
- 治疗 /
- 病毒学应答
Abstract: At present,long- acting interferon combined with ribavirin is still a major therapeutic method for hepatitis C in China,and precision medicine can help cure more patients with hepatitis C. This article briefly introduces the diagnosis and treatment of hepatitis in China and the importance of the strategy of virologic response- guided therapy( RGT),and analyzes the influencing factors for the achievement of sustained virologic response. HCV RNA quantitation is the foundation of RGT strategy,and HCV RNA quantitation with a high specificity performed at crucial time points during treatment helps to evaluate response accurately,realize the individualized treatment of hepatitis C,and improve the cure rate of hepatitis C.
- hepatitis C /
- therapy /
- virological response

HTML全文

参考文献(17)

[1] COLLINS FS,VARMUS H.A new initiative on precision medicine[J].N Engl Med,2015,372(9):793-795.

[2]JAMESON JL,LONGO DL.Precision medicine---personalized,problematic,and promising[J].N Engl Med,2015,372(23):2229-2234.

[3]MOHD HANAFIAH K,GROEGER J,FLAXMAN AD,et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333-1342.

[4]MAJUMDAR A,KITSON MT,ROBERTS SK.Systematic review:current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis[J].Aliment Pharmacol Ther,2016,43(12):1276-1292.

[5]GUTIERREZ JA,LAWITZ EJ,POORDAD F.Interferon-free,direct-acting antiviral therapy for chronic hepatitis C[J].Viral Hepat,2015,22(11):861-870.

[6]RAO H,WEI L,LOPEZ-TALAVERA JC,et al.Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J].J Gastroenterol Hepatol,2014,29(3):545-553.

[7]LEE MH,YANG HI,LU SN,et al.Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases:a community-based long-term prospective study[J].J Infect Dis,2012,206(4):469-477.

[8]LEE MH,YANG HI,LU SN,et al.Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma[J].Int J Cancer,2014,135(5):1119-1126.

[9]WEI L.Present situation of hepatitis C virus antiviral therapy and application prospects of small molecule drugs in our country[J].Chin J Hepatol,2013,21(6):403-405.魏来.我国丙型肝炎抗病毒治疗现状与小分子药物的应用前景[J].中华肝脏病杂志,2013,21(6):403-405.

[10]YU ML,DAI CY,HUANG JF,et al.Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients:a rondomized trial[J].Hepatology,2008,47(6):1884-1893.

[11]HUANG CF,YANG JF,HUANG JF,et al.Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response[J].J Gastroenterol Hepatol,2010,25(4):758-765.

[12]SWAIN MG,LAI MY,SHIFFMAN ML,et al.A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin[J].Gastroenterology,2010,139(5):1593-1601.

[13]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学会分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979.

[14]OMATA M,KANDA T,WEI L,et al.APASL consensus statements and recommendation on treatment of hepatitis C[J].Hepatol Int,2016.[Epub ahead of print]

[15]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol,2015,63(1):199-236.

[16]WANG J,JIN Q,RAO HY,et al.Comparison of domestic reagents and Roche COBAS Taq Man in rapid and early virological response in patients with chronic hepatitis C[J].Infect Dis Info,2012,25(3):177-179.(in Chinese)王剑,金茜,饶慧瑛,等.国产试剂与Roche COBAS Taq Man试剂对慢性丙型肝炎快速和早期病毒学应答的比较研究[J].传染病信息,2012,25(3):177-179.

[17]WHO Guidelines Approved by the Guidelines Review Committee.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection:updated version[EB/OL].http://www.who.int/publications/guidelines/en/

施引文献

资源附件(0)

访问统计